P2X₇ Receptor and Polykarion Formation

Simonetta Falzoni,* Paola Chiozzi,* Davide Ferrari,* Gary Buell,⁺ and Francesco Di Virgilio^{*‡}

*Department of Experimental and Diagnostic Medicine, Section of General Pathology, and *Biotechnology Center, University of Ferrara, Ferrara, Italy; and *Serono Pharmaceutical Research Institute, Geneva, Switzerland

Submitted January 19, 2000; Revised May 25, 2000; Accepted July 6, 2000 Monitoring Editor: Guido Guidotti

Cell fusion is a central phenomenon during the immune response that leads to formation of large elements called multinucleated giant cells (MGCs) of common occurrence at sites of granulomatous inflammation. We have previously reported on the involvement in this event of a novel receptor expressed to high level by mononuclear phagocytes, the purinergic P2X₇ receptor. Herein, we show that blockade of this receptor by a specific monoclonal antibody prevents fusion in vitro. In contrast, cell fusion is stimulated by addition of enzymes that destroy extracellular ATP (i.e., apyrase or hexokinase). Experiments performed with phagocytes selected for high (P2X₇ hyper) or low (P2X₇ hypo) P2X₇ expression show that fusion only occurs between P2X₇ hyper/P2X₇ hyper and not between P2X₇ hyper/P2X₇ hypo or P2X₇ hypo/P2X₇ hypo. During MGCs formation we detected activation of caspase 3, an enzyme that is powerfully stimulated by P2X₇. Finally, we observed that during MGCs formation, the P2X₇ receptor is preferentially localized at sites of cell-to-cell contact. These findings support the hypothesis originally put forward by our group that the P2X₇ receptor participates in multinucleated giant cell formation.

INTRODUCTION

During the immune response it is frequently observed that mononuclear phagocytes fuse to generate large elements called multinucleated giant cells (MGCs) (Fais et al., 1997). It is common to find these polykarions at sites of chronic inflammation such as granulomas, whether due to bacterial pathogens or sterile foreign bodies, or as a consequence of viral infections such as acquired immunodeficiency syndrome (Cotran et al., 1994). It is known that fusion requires macrophage activation by cytokines released by T lymphocytes, among which the most important appear to be interleukin (IL)-4, interferon- γ , and tumor necrosis factor- α , but the molecular mechanism involved is still mysterious. Multinucleation also occurs in the bone during osteoclast formation under the effect of locally released cytokines (Vignery, 1989; Suda et al., 1995). Apart from osteoclasts that acquire an increased bone resorption capability after fusion, the physiological meaning of MGC formation is unknown, albeit a number of suggestions have been put forward (enhanced cytokine producing activity, a nonphagocytic pathway for antigen internalization, a mechanism for disposing

infected or damaged monocytes). Likewise, the molecular mechanism that drives fusion is unknown. A few plasma membrane molecules probably involved have been identified such as intercellular adhesion molecule-1, leukocyte function–associated antigen-1, E-cadherins, CD98, CD44, or the newly cloned macrophage fusion receptor (Saginario *et al.*, 1998; Sterling *et al.*, 1998), but it appears that fusion does not depend on the engagement of a single receptor, but rather on the recruitement of several molecules mediating cell aggregation, establishment of close cell-to-cell contacts, and finally the actual fusion event.

Over the last years we have extensively characterized a plasma membrane receptor belonging to the subfamily of the P2X purinergic receptors, named P2X₇ that is expressed to a very high level by macrophage, microglial, and dendritic cells (Ferrari et al., 1996; Chiozzi et al., 1997; Coutinho-Silva et al., 1999; Mutini et al., 1999). P2X₇ is a ligand-gated receptor/channel formed by an unknown number of subunits each 595 amino acids long that upon sustained stimulation with ATP causes the formation of a nonselective pore permeable to low-molecular-weight aqueous solutes (Di Virgilio, 1995; Surprenant et al., 1996; Rassendren et al., 1997). This receptor was initially identified and characterized in immune cells (Di Virgilio et al., 1995), and eventually cloned from a rat brain library (Surprenant et al., 1996). Cloning from a brain library was not surprising because, although central neurons are basically negative for P2X₇, microglia is one of the cell types that expresses $P2X_7$ to the highest level.

[‡] Author correspondence to: E-mail address: fdv@dns.unife.it. Abbreviations used: FSDC, fetal skin-derived dendritic cell; MGC, multinucleated giant cell; oATP, oxidized ATP; P2X₇ hyper, phagocytes hyperexpressing the P2X₇ receptor; P2X₇ hypo, phagocytes hypoexpressing the P2X₇ receptor.

In mononuclear phagocytes P2X₇ has been associated to cytotoxicity and to maturation and release of IL-1 β (Ferrari et al., 1997a; Di Virgilio et al., 1998a), but it has been suggested that it also might participate in MGC formation (Chiozzi *et al.*, 1997). The first indication of a role for $P2X_7$ in macrophage fusion came from experiments performed in our laboratory showing that multinucleation of monocytederived human macrophages in vitro was efficiently prevented by the P2X₇ blocker oxidized ATP (oATP) (Falzoni et al., 1995). Subsequently, we showed that macrophage cell clones expressing $P2X_7$ to a very high level ($P2X_7$ hyper) spontaneously fuse during in vitro culture, whereas clones selected for lack of P2X₇ (P2X₇ hypo) never do (Chiozzi et al., 1997). The step at which P2X₇ takes part in cell fusion is at present unknown, but we speculate that it might be involved in the very last step of the process, the actual membrane fusion, with a mechanism reminiscent of that of the better known "fusion pore" putatively involved in the fusion of synaptic vesicles with the plasma membrane (Monck and Fernandez, 1996). In the present work we provide further evidence for the involvement of P2X₇ in MGC formation.

MATERIALS AND METHODS

Cells

J774 mouse macrophages and P2X₇ hyper and P2X₇ hypo clones were grown in Dulbecco modified Eagle's medium (Sigma, St. Louis, MO) supplemented with 2 mM glutamine, 10% heat-inactivated horse serum, penicillin (100 units [U]/ml), and streptomycin (100 μ g/ml). P2X₇ hyper and P2X₇ hypo variants were selected as described previously (Chiozzi *et al.*, 1996, 1997). Fetal skin-derived dendritic cells (FSDCs) were grown in Iscove medium (Sigma) containing 50 μ M 2-mercaptoethanol, 2 mM glutamine, 10% heatinactivated fetal calf serum (Life Technologies, Paisley, Scotland), penicillin (100 U/ml), and streptomycin (100 μ g/ml) as previously described (Mutini *et al.*, 1999). Human monocytes were isolated from buffy coats by one-step Percoll gradient (Pharmacia Biotech Spa, Cologno Monzese, Italy) or by adherence on plastic Petri dishes as previously described (Falzoni *et al.*, 1995).

Antibodies

The antihuman $P2X_7$ monoclonal antibody (mAb) was previously characterized by Buell *et al.* (1998). The polyclonal anti- $P2X_7$ Ab was previously characterized by Solini *et al.* (1999). Fluorescein isothiocyanate (FITC)-conjugated Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Immunofluorescence

Cells were fixed in 2% paraformaldehyde/phosphate-buffered saline (PBS), pH 7.3, for 1 h at 4°C, and then rinsed three times with ice-cold PBS and incubated in 100 mM ammonium chloride for 20 min. At the end of this incubation, the monolayers were thoroughly rinsed with PBS, incubated with the 2.4G2 mAb (anti-Fc receptor) for a further 20 min at 4°C, and again rinsed with ice-cold PBS. Incubation with the polyclonal anti-P2X₇ Ab (Solini *et al.*, 1999) was performed overnight at 4°C at a dilution of 1:50. For immunofluorescence, the secondary Fluorescein isothiocyanate-conjugated Ab was used at a 1:200 dilution (40 min at 4°C).

Caspase Activation

Caspase 3 activation was measured fluorometrically with the Enz-Check Caspase 3 kit (Molecular Probes, Eugene, OR), as indicated by the manufacturer.

ATP Measurement

Monocyte-derived macrophages were seeded in microtiter plastic dishes in a total volume of culture medium of 100 μ l in the presence or absence of concanavalin A (ConA) (10 μ g/ml) and placed in a CO₂ incubator at 37° for 24 h. After this time, cells were rinsed and supplemented with 100 μ l of diluent buffer (FireZyme, San Diego, CA) to stabilize extracellular ATP, and placed directly in the test chamber of a luminometer (FireZyme). Then 100 μ l of a luciferin–luciferase solution (FireZyme) was added, and light emission was recorded.

Microscopy

Phase contrast and fluorescence photographs were taken with an inverted fluorescence microscope (Olympus IMT-2; Olympus Optical, Tokyo, Japan) equipped with 20 and $40 \times$ objectives and fluorescein and rhodamine filters. Some images also were taken with a Nikon Eclipse TE-300 fluorescence microscope (Nikon, Tokyo, Japan) equipped with 40, 63, and $100 \times$ (oil immersion) objectives.

RESULTS

We have observed that fusion spontaneously occurs in in vitro cultures of mononuclear phagocytes clones derived from J774 macrophages as well as dendritic cells derived from mouse skin (FSDCs) that express high levels of the P2X₇ receptor




Figure 1. An anti-P2X₇ mAb blocks MGC formation. Monocytes were isolated from peripheral blood and plated as described in MATERIALS AND METHODS. ConA (10 μ g/ml) was added soon after the plating and incubation carried on for 3 days. (B) Anti-P2X₇ mAb (10 μ g/ml) was added together with ConA.




Figure 2. Enhanced MGC formation in macrophage monolayers incubated in the presence of ATP-hydrolyzing enzymes. $P2X_7$ hyper J774 macrophages were plated in 24-well plates and grown to confluence. At this time, hexokinase (100 μ g/ml) (B) or apyrase (0.4 U/ml) (D) was added and the incubation further carried out for 24 h. A and C, parallel control cultures in the absence of the ATP-hydrolyzing enzymes.

(P2X₇ hyper clones) (Chiozzi *et al.*, 1997; Chiozzi, Falzoni, and Di Virgilio, unpublished observations). Furthermore, fusion can be induced in primary cultures of human monocytes by incubation in the presence of ConA or phytohemagglutinin (PHA) (Takashima *et al.*, 1993; Falzoni *et al.*, 1995).

Recently, Buell et al. (1998) raised and fully characterized an inhibitory mAb directed against the outer domain of human P2X₇. Pretreatment with this mAb blocked several macrophage responses dependent on P2X₇ activation, including cytotoxicity and IL-1 β release (Buell *et al.*, 1998). Our preliminary evidence suggested that this mAb also could prevent polykarion formation (Di Virgilio et al., 1999). Thus, we tested more thoroughly the effect of the anti-P2X₇ mAb on ConA-stimulated fusion of monocyte-derived human macrophages. Figure 1 shows that this mAb almost completely blocked MGC formation, but very interestingly, did not prevent cell aggregation, suggesting that chemotaxis and surface molecule recognition were not affected. Fusion index of six different ConA-stimulated monocyte preparations ranged from 61 to 85%, and was not affected by incubation in the presence of irrelevant mouse IgG. Pretreatment with the anti-P2X₇ mAb brought the fusion index close to zero in all monolayers examined.

Blocking of fusion by a selective anti-P2X₇ mAb is a strong indication that this receptor participates in MGC formation.

Vol. 11, September 2000

However, if a functional P2X₇ is needed for membrane fusion, one could expect that its activation by exogenous ATP facilitated fusion. We tested this hypothesis on J774 and FSDC P2X₇ hyper clones that spontaneously undergo fusion in culture, and found that this was not the case because incubation in the presence of a range of ATP concentrations sufficient to activate the P2X₇ receptor (1-5 mM) inhibited fusion. In contrast, the presence in the incubation medium of ATP-hydrolyzing enzymes such as hexokinase or apyrase powerfully enhanced MGC formation in the P2X₇ hyper clones (Figure 2). Boiling abolished apyrase and hexokinase fusogenic activity. In hindsight, the effect of apyrase and hexokinase was not totally unexpected because we and others have previously shown that in some cell types P2 receptors are chronically desensitized by the continuous leak of ATP into the pericellular medium, and that hexokinase or apyrase reestablish sensitivity to stimulation by ATP (Baricordi et al., 1996; Buell et al., 1996). Phagocytes release significant amounts of ATP into the pericellular milieu, thus it is likely that their P2X₇ receptor is exposed to high extracellular ATP concentrations, especially when they come in close contact before fusion. We measured bulk extracellular ATP before and during fusion in six different monocytederived macrophage monolayers, and found that it ranged from 250 to 592 pmol/106 cells in unstimulated cultures, and




Figure 3. Fusion index of apyrase- or hexokinase-treated macrophage monolayers. The fusion index was determined by counting the (number of nuclei within MGCs)/(total number of nuclei counted) \times 100. We identified as MGCs those cells that had more than two nuclei per cell. Three different microscopic fields were counted in three different MGC preparations. Data are average \pm SD of nine determinations.

from 410 to 1010 pmol/10⁶ cells after 24 h of stimulation with ConA. Figure 3 reports the fusion index calculated in several P2X₇ hyper or P2X₇ hypo J774 monolayers incubated in the absence or presence of ATP-consuming enzymes. It is noteworthy that these agents did not trigger fusion in cells lacking P2X₇. Neither apyrase nor hexokinase could be used to enhance fusion of monocyte-derived macrophages because in the presence of ConA or PHA, these enzymes had a surprising toxic effect hallmarked by swelling, rounding, and vesiculation of the cells.

Hexokinase and apyrase, by increasing the rate of degradation of extracellular ATP, also might enhance accumulation of extracellular adenosine. Activation of A1 receptors has been shown to enhance MGC formation stimulated by phorbol 12-myristate 13-acetate in human monocyte cultures (Merril et al., 1997). Under our experimental conditions, adenosine had no effect of cell fusion over a range of concentrations from 1 to 100 μ M, in fact it was inhibitory at the higher dose. We then tested the effect of adenosine deaminase, an enzyme that destroys extracellular adenosine, on two fusion models: apyrase- or hexokinase-stimulated P2X₇ hyper J774 macrophages, and PHA- or apyrase-stimulated FSDCs (Figure 4). Adenosine deaminase slightly enhanced fusion by itself, and also potentiated MGC formation in the presence of the additional stimulants, but the increase never reached statistical significance, suggesting that albeit adenosine can stimulate fusion, it is not the main factor under our experimental conditions.

As shown in Figure 4 and by Chiozzi *et al.* (1997), $P2X_7$ hypo macrophage clones are unable to fuse in culture, in striking contrast to their $P2X_7$ hyper partners. We then asked





Figure 4. Effect of adenosine deaminase on MGC formation. The fusion index was determined as detailed in Figure 3. P2X₇ hyper and P2X₇ hypo J774 cells were treated with hexokinase (HEXO) or apyrase (APY) and processed as described in Figure 2. FSDCs were incubated in the presence of PHA (10 μ g/ml) or apyrase (0.4 U/ml) for 2 d before determination of fused cells. Adenosine deaminase was added at a concentration of 2 U/ml. C, control. Data are average \pm SD of six determinations.

whether expression of P2X₇ is needed on both partner cells undergoing fusion, or in other words, whether a P2X₇ hypo cell can fuse with a P2X₇ hyper, or fusion can only occur between P2X₇ hyper cells. To answer this question, we labeled P2X₇ hypo and P2X₇ hyper FSDCs with Texas Red and lucifer yellow, respectively, and then coincubated the two cell populations. Our anticipation was that if fusion occurred between P2X₇ hyper and P2X₇ hypo cells we should find MGC stained with both the red and the yellow/green stain, whereas if fusion only occurred between P2X₇ hyper we should only see MGC stained in yellow/green. Figure 5 shows that by mixing Texas Red-stained P2X7 hypo and lucifer yellow-stained P2X₇ hyper FSDCs, we obtained the formation of MGCs that were almost exclusively stained in yellow/green. In >10 separate, similar experiments, we calculated that ~95-98% of MGCs were exclusively lucifer vellow positive. The residual small percentage of cells was positive for both stains due, we suggest, to the presence of some P2X₇-positive cells within the P2X₇ hypo population (see also Chiozzi et al., 1997).

As of now, there are very few means to monitor activation of $P2X_7$, the best and most reliable being conductance (Surprenant *et al.*, 1996) or fluorescent dye uptake measurements (Steinberg *et al.*, 1987). However, it is very difficult to apply



A B




Figure 5. MGC formation requires $P2X_7$ receptor expression on all cells participating to fusion. $P2X_7$ hyper and $P2X_7$ hypo FSDCs were allowed to pinocytose lucifer yellow (1 mg/ml) or Texas Red (0.4 mg/ml), respectively, for 3 h. At the end of this incubation time, the two batches were mixed in the well of a 24-well culture dish, and further incubated for 3 days. (A) Phase. (B) Rhodamine filter. (C) Fluorescein filter.

these techniques to the measurement of P2X₇ opening during cell fusion because patch clamp significantly perturbs the cellular microenvironment and dye uptake does not allow an easy quantification. We monitored lucifer yellow uptake in ConA-stimulated cultures of monocyte-derived

Figure 6. Spontaneous and selective lucifer yellow uptake by fusing monocyte-derived macrophages. Monocytes were isolated from peripheral blood and plated as described in MATERIALS AND METHODS. ConA (10 μ g/ml) was added soon after the plating. The picture was taken after 24 h of incubation in the presence of ConA.

macrophages and observed that cells involved in fusion showed an increased dye uptake (Figure 6, A and B). However, we also felt that dye uptake was an unsatisfactory assay for $P2X_7$ activation under these experimental conditions because by this means we might miss opening of those receptors located on the tightly juxtapposed plasma membranes of closely juxtaposed cells (i.e., the very cells that are about to fuse), and that presumably are segregated from the extracellular milieu. Ferrari *et al.* (1999) showed that stimulation of $P2X_7$ causes a large stimulation of caspase 3. We




Figure 7. Caspase 3 activation during cell fusion. Cells were seeded in 24-well culture plates and incubated either in culture medium alone (C) or in culture medium supplemented with ConA (10 μ g/ml) for human macrophages, PHA (10 μ g/ml) for FSDCs, and hexokinase (HEXO) for J774 macrophages. In some experiments, oATP (300 μ M) or KN-62 (50 nM) also were added. After 2 d, when MGC formation was maximal, the monolayers cells were rinsed several times, lysed in lysis buffer provided with the Enz-Check kit, and assayed for caspase 3 activation. Data are average \pm SD of six determinations.

therefore asked whether this cystein protease is activated during macrophage fusion, and can thus be used as an indicator of P2X₇ opening. Caspase 3 activity was measured at peak time for fusion in four different cell types: human monocyte-derived macrophages, FSDCs, P2X₇ hyper, and P2X₇ hypo J774 macrophages (Figure 7). Monocyte-derived human macrophages in culture were stimulated to fuse with Con A, FSDCs with PHA, and P2X₇ hyper and P2X₇ hypo cells with hexokinase, and were then processed for caspase 3 activation measurement. In all cell models, with the exception of the $P2X_7$ hypo variant that is unable to fuse, there was a large caspase 3 stimulation, very likely due to P2X₇ activation because it 1) was inhibited by two specific $P2X_7$ blockers, oATP and 1-[N,O-bis(5-isoquinolinesulphonyl)-Nmethyl-L-tyrosyl]-4-phenylpiperazine (KN-62) (Murgia et al., 1993; Gargett and Wiley, 1997); and 2) did not occur in the $P2X_7$ hypo variant.

We then investigated the cellular distribution of $P2X_7$ during the fusion process, asking whether there was an increased localization of this receptor at sites of cell-to-cell contact during MGC formation in human monocyte-derived macrophage cultures induced to fuse with ConA. Figure 8A shows the stage at which the culture was fixed and stained with the anti-P2X₇ polyclonal Ab (after 1 day of culture in the presence of ConA): some MGCs were already formed and were growing in size by recruiting nearby macrophages. Podosomes projected from the cell body of the incoming macrophages (arrows) and established contact with the MGC plasma membrane. Staining with the anti- $P2X_7$ Ab revealed discrete patches at the level of the plasma membrane (Figure 8B) that at a higher magnification appeared to be more concentrated at sites of cell-to-cell interaction, especially at the tip of the podosome (Figure 8, C and D). Figure 8E shows a control experiment performed with pre-immune rabbit serum.

DISCUSSION

There is increasing awareness that mononuclear phagocytes express plasma membrane receptors for extracellular nucleotides that are likely to have a mediator role during the inflammatory reaction (Di Virgilio, 1995; Ferrari et al., 1996; Humphreys and Dubyak, 1996; Mutini et al., 1999; Sikora et al., 1999). These receptors belong to the P2Y (G-proteincoupled, seven-membrane-spanning receptors) or to the P2X (intrinsic ligand-gated ion channels) subfamilies (Burnstock, 1997; Ralevic and Burnstock, 1998). In particular, macrophage, microglial, and dendritic cells express to a high level the most peculiar member of the P2X subfamily, P2X₇. This is a bifunctional receptor that although upon transient stimulation with ATP behaves as a typical cation-selective ion channel permeable to K⁺, Na⁺, and Ca²⁺, upon repetitive stimulation undergoes a transition into a nonselective pore that also allows transmembrane fluxes of low-molecular-mass hydrophylic molecules up to 900 Da. There is no clear-cut physiological function for such a receptor as yet, but it is clearly intriguing that it is up-regulated during monocyte-to-macrophage differentiation and by those stimuli that cause macrophage activation such as interferon- γ , and in some cases also bacterial endotoxin and tumor necrosis factor (Falzoni et al., 1995; Humphreys and Dubyak, 1996; Di Virgilio et al., 1998b). Due to the availability of a highly selective inhibitor of P2X₇, the mAb originally described by Buell et al. (1998), and used in the present work, we are now able to provide strong support to our original hypothesis on the involvement of this receptor in MGC formation. This mAb specifically recognizes an epitope located on the outer domain of the P2X₇ receptor, and the ability to almost completely prevent MGC formation is crucial evidence for the participation of this receptor in macrophage fusion. This is in keeping with the ability of this mAb to block other P2X₇-dependent responses such as transmembrane ion fluxes and IL-1 β release (Buell *et al.*, 1998). The step in the fusion process in which P2X₇ takes part is however still uncertain. We think that because macrophage clustering in the presence of the mAb is not inhibited, P2X₇ does not act as a chemotactic or cell adhesion receptor, but rather intervenes in the very last phase of membrane fusion, maybe generating a "fusion pore" that establishes early bridges between the cytoplasm of the adjacent cells and drives the eventual fusion. In other words, it could be hypothesized that to form an efficient fusion pore it is necessary that at least two P2X₇ receptors on opposite plasma membranes come in contact via their extracellular domains, not dissimilarly from the mechanism whereby gap-junctional communication is established by the hemi-gap junctions expressed on the membrane of adjacent cells. The finding of an oATP and KN-62 inhibitable caspase 3 activation during fusion




Figure 8. Immunolocalization of P2X7 receptor during MGC formation. Monocyte-derived human macrophages were seeded in 24-well culture plates and stimulated with ConA (10 µg/ml). At the beginning of fusion (24 h after the seeding), cells were fixed and immunostained as described in MATERIALS AND METHODS. (A) Phase. (B-E) Fluorescence.

supports the hypothesis that P2X₇ transiently opens, but further experiments are needed to provide unequivocal evidence.

A related question is what turns on P2X₇ during fusion. We anticipated that the trigger could be the P2X₇ physiological ligand, i.e. extracellular ATP; however, this turned out not to be the case because addition of ATP to the macrophage monolayers, if anything, inhibited fusion. In hindsight, this was not entirely unexpected because it is clear that, in order to allow membrane fusion, opening of the $P2X_7$ pore must be strictly controlled and occur only when the opposing plasma membranes are tightly juxtapposed and ready to merge. In contrast, the mere addition of ATP to a macrophage monolayer very likely activates P2X₇ in an untimely manner, with an overall detrimental effect on cell fusion. Thus, we think that the trigger could be a surface molecule, maybe $P2X_7$ itself, on the opposing membrane. This interpretation received some support from the facilitating effect of apyrase and hexokinase. These two enzymes efficiently hydrolyze extracellular ATP, and have been shown to restore sensitivity of P2X receptors desensitized by the chronic leakage of ATP that is known to occur from many cell types, macrophages included (Baricordi et al., 1996; Buell et al., 1996; Ferrari et al., 1997b). Thus, it is

possible that under normal conditions P2X₇ receptors are partially desensitized by the continuous leakage of ATP, or even stably occupied by this nucleotide, and therefore unavailable for fusion. Removal of ATP by apyrase or hexokinase would reestablish P2X₇ sensitivity and thus accelerate fusion. Localization of P2X7 during MGC formation supports our hypothesis. In resting macrophages and MGCs $P2X_7$ is uniformly distributed on the plasma membrane, but during fusion it concentrates in discrete membrane clusters at the site of cell-to-cell interaction.

In conclusion, our data support a role for $P2X_7$ as a novel plasma membrane receptor involved in macrophage fusion and MGC formation.

ACKNOWLEDGMENTS

This study was supported by the Italian Ministry for Scientific Research (40 and 60%), the National Research Council of Italy (Target Project on Biotechnology), the Italian Association for Cancer Research (AIRC), the IX AIDS Project, the II Tuberculosis Project, and Telethon of Italy. A preliminary account of these results was presented at the Keystone Symposium on Macropahge Biology (Keystone, Colorado, January 22-28, 1999).

REFERENCES

Baricordi, O.R., Ferrari, D., Melchiorri, L., Chiozzi, P., Hanau, S., Chiari, E., Rubini, M., and Di Virgilio, F. (1996). An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood *87*, 682–690.

Buell, G.N., Chessel, I.P., Michel, A.D., Collo, G., Salazzo, M., Herren, S., Gretner, D., Grahames, C., Kaur, R., Kosco-Vilbois, M.H., and Humphrey, P.P.A. (1998). Blockade of human P2X₇ receptor function with a monoclonal antibody. Blood *92*, 3521–3528.

Buell, G., Michel, A.D., Lewis, C., Collo, G., Humphrey, P.P.A., and Surprenant, A. (1996). P2X₁ receptor activation in HL60 cells. Blood *87*, 2659–2664.

Burnstock, G. (1997). The past, present and future of purine nucleotides as signaling molecules. Neuropharmacology *36*, 1127–1139.

Chiozzi, P., Murgia, M., Falzoni, S., Ferrari, D., and Di Virgilio, F. (1996). Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. Biochem. Biophys. Res. Commun. *218*, 176–181.

Chiozzi, P., Sanz, J.M., Ferrari, D., Falzoni, S., Aleotti, A., Buell, G.N., Collo, G., and Di Virgilio, F. (1997). Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X₇ receptor. J. Cell Biol. *138*, 697–706.

Cotran, R.S., Kumar, V., and Robbins, S.L. (1994). Pathologic basis of diseases. Philadelphia: WB Saunders Company.

Coutinho-Silva, R., Persechini, P.M., Da Cunha Bisaggio, R.D., Perfettini, J.-L., Torres de Sa Neto, A.C., Kanellopulos, J.M., Motta-Ly, L., Dautry-Varsat, A., and Ojcius, D.M. (1999). P2Z/P2X₇ receptor-dependent apoptosis of dendritic cells. Am. J. Physiol. 276, C1139–C1147.

Di Virgilio, F. (1995). The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol. Today *16*, 524–528.

Di Virgilio, F., Chiozzi, P., Falzoni, S., Ferrari, D., Sanz, J.M., Vishwanath, V., and Baricordi, O.R. (1998a). Cytolytic P2Z purinoceptors. Cell Death Differ. 5, 191–199.

Di Virgilio, F., Falzoni, S., Chiozzi, I.P., Sanz, J.M., Ferrari, D., and Buell, G.N. (1999). ATP receptors and giant cell formation. J. Leukocyte Biol. *66*, 723–726.

Di Virgilio, F., Falzoni, S., Mutini, C., Sanz, J.M., and Chiozzi, P. (1998b). Purinergic $P2X_7$ receptor: a pivotal role in inflammation and immunomodulation. Drug Dev. Res. 45, 207–213.

Fais, S., Burgio, V.L., Capobianchi, M.R., Gessani, S., Pallone, F., and Belardelli, F. (1997). The biological relevance of polykarions in the immune response. Immunol. Today *18*, 522–527.

Falzoni, S., Munerati, M., Ferrari, D., Spisani, S., Moretti, S., and Di Virgilio, F. (1995). The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. J. Clin. Invest. 95, 1207–1216.

Ferrari, D., Chiozzi, P., Falzoni, S., Dal Susino, M., Melchiorri, L., Baricordi, O.R., and Di Virgilio, F. (1997a). Extracellular ATP triggers IL-1 β release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. *159*, 1451–1458.

Ferrari, D., Chiozzi, P., Falzoni, S., Hanau, S., and Di Virgilio, F. (1997b). Purinergic modulation of interleukin-1 β release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med. *185*, 579–582.

Ferrari, D., Los, M., Bauer, M.K.A., Vandenabeele, P., Wesselborg, S., and Schulze-Osthoff, S. (1999). P2Z purinoceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett. 447, 71–75.

Ferrari, D., Villalba, M., Chiozzi, P., Falzoni, S., Ricciardi-Castagnoli, P., and Di Virgilio, F. (1996). Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. J. Immunol. *156*, 1531–1539.

Gargett, C.E., and Wiley, J.S. (1997). The isoquinoline derivative KN-62: a potent antagonist of the P2Z-receptor of human lymphocytes. Br. J. Pharmacol. *120*, 1483–1490.

Humphreys, B.D., and Dubyak, G.R. (1996). Induction of the P2Z/P2X₇ nucleotide receptor and associated phospholipase D activity by lipopolysaccharide and IFN- γ in the human THP-1 monocytic cell line. J. Immunol. *157*, 5627–5637.

Merril, J.T., Shen, C., Schreibman, D., Coffey, D., Zakharenko, O., Fisher, R., Lahita, R.G., Salmon, J., and Cronstein, B.N. (1997). Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum 40, 1308–1315.

Monck, J.R., and Fernandez, J.M. (1996). The fusion pore and mechanisms of biological membrane fusion. Curr. Opin. Cell Biol. *8*, 524–533.

Murgia, M., Hanau, S., Pizzo, P., Rippa, M., and Di Virgilio, F. (1993). Oxidized ATP: an irreversible inhibitor of the macrophage purinergic P2Z receptor. J. Biol. Chem. 268, 8199–8203.

Mutini, C., Falzoni, S., Ferrari, D., Chiozzi, P., Morelli, A., Baricordi, O.R., Collo, G., Ricciardi-Castagnoli, P., and Di Virgilio, F. (1999). Mouse dendritic cells express the $P2X_7$ purinergic receptor: characterization and possible participation in antigen presentation. J. Immunol. *163*, 1958–1965.

Ralevic, V., and Burnstock, G. (1998). Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413–492.

Rassendren, F., Buell, G.N., Virginio, C., Collo, G., North, R.A., and Surprenant, A. (1997). The permeabilizing ATP receptor $P2X_7$: cloning of a human cDNA. J. Biol. Chem. 272, 5482–5486.

Saginario, C., Sterling, H., Beckers, C., Kobayashi, R., Solimena, M., Ullu, E., and Vignery, A. (1998). MFR, a putative receptor mediating the fusion of macrophages. Mol. Cell. Biol. *18*, 6213–6223.

Sikora, A., Liu, J., Brosnan, C., Buell, G., Chessel, I., and Bloom, B.R. (1999). Cutting edge: purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X₇independent mechanism. J. Immunol. *163*, 558–561.

Solini, A., Chiozzi, P., Morelli, A., Fellin, R., and Di Virgilio, F. (1999). Human primary fibroblasts in vitro express a purinergic $P2X_7$ receptor coupled to ion fluxes, miscrovesicle formation and IL-6 release. J. Cell Sci. *112*, 297–305.

Steinberg, T.H., Newman, A.S., Swanson, J.A., and Silverstein, S.C. (1987). ATP^{4–} permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J. Biol. Chem. *262*, 8884–8888.

Sterling, H., Saginario, C., and Vignery, A. (1998). CD44 occupancy prevents macrophage multinucleation. J. Cell Biol. *143*, 837–847.

Suda, T., Udagawa, N., Nakamura, I., Miyaura, C., and Takahashi, N. (1995). Modulation of osteoclast differentiation by local factors. Bone *17*, S87S–S91.

Surprenant, A., Rassendren, F., Kawashima, E., North, R.A., and Buell, G. (1996). The cytolytic P2Z receptor for extracellular ATP identified as a P2X ($P2X_7$) receptor. Science 272, 735–738.

Takashima, T., Ohnishi, K., Tsuyuguchi, I., and Kishimoto, S. (1993). Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN- γ and IL-4. J. Immunol. *150*, 3002–3007.

Vignery, A. (1989). Macrophage multinucleation is accompanied by the expression of new soluble and membrane antigens in mice. Am. J. Pathol. *135*, 565–570.

Molecular Biology of the Cell